PL2661261T3 - Formulacje immunosupresyjne - Google Patents

Formulacje immunosupresyjne

Info

Publication number: PL2661261T3
Authority: PL; Poland
Prior art keywords: immunosuppressant; formulations; immunosuppressant formulations
Prior art date: 2011-01-07

Application number

PL12700262T

Other languages

English (en)

Inventor

Philippe BOUILLOT

Emeric Reynaud

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-07

Filing date

2012-01-05

Publication date

2020-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44022942&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2661261(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-01-05 Application filed by Novartis Ag filed Critical Novartis Ag

2020-01-31 Publication of PL2661261T3 publication Critical patent/PL2661261T3/pl

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Orthopedic Medicine & Surgery (AREA)
Biomedical Technology (AREA)
Transplantation (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PL12700262T 2011-01-07 2012-01-05 Formulacje immunosupresyjne PL2661261T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP11150431		2011-01-07
PCT/EP2012/050151 WO2012093161A1 (en)	2011-01-07	2012-01-05	Immunosuppressant formulations
EP12700262.4A EP2661261B1 (en)	2011-01-07	2012-01-05	Immunosuppressant formulations

Publications (1)

Publication Number	Publication Date
PL2661261T3 true PL2661261T3 (pl)	2020-01-31

Family

ID=44022942

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL12700262T PL2661261T3 (pl)	2011-01-07	2012-01-05	Formulacje immunosupresyjne

Country Status (36)

Country	Link
US (4)	US20130273161A1 (pl)
EP (2)	EP3590507A1 (pl)
JP (2)	JP6111202B2 (pl)
KR (2)	KR102166885B1 (pl)
CN (1)	CN103458877B (pl)
AR (2)	AR084801A1 (pl)
AU (1)	AU2012204835B2 (pl)
BR (1)	BR112013017302B1 (pl)
CA (1)	CA2823616C (pl)
CL (1)	CL2013001979A1 (pl)
CO (1)	CO6761402A2 (pl)
CY (1)	CY1122182T1 (pl)
DK (1)	DK2661261T3 (pl)
EA (1)	EA026144B9 (pl)
EC (1)	ECSP13012812A (pl)
ES (1)	ES2751920T3 (pl)
GT (1)	GT201300178A (pl)
HR (1)	HRP20191842T1 (pl)
HU (1)	HUE045612T2 (pl)
IL (1)	IL227094B (pl)
JO (1)	JO3619B1 (pl)
LT (1)	LT2661261T (pl)
MA (1)	MA34897B1 (pl)
MX (2)	MX357304B (pl)
MY (1)	MY161162A (pl)
PE (1)	PE20140216A1 (pl)
PH (1)	PH12013501442B1 (pl)
PL (1)	PL2661261T3 (pl)
PT (1)	PT2661261T (pl)
SG (1)	SG191286A1 (pl)
SI (1)	SI2661261T1 (pl)
TN (1)	TN2013000257A1 (pl)
TW (2)	TWI610672B (pl)
UA (1)	UA114283C2 (pl)
WO (1)	WO2012093161A1 (pl)
ZA (1)	ZA201304465B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2661261T (pt)	2011-01-07	2019-10-25	Novartis Ag	Formulações imunossupressoras.
CN106456552A (zh) *	2014-04-10	2017-02-22	诺华股份有限公司	S1p调节剂的立即释放剂量方案
CN106163502B (zh)	2014-04-10	2020-12-01	诺华股份有限公司	免疫抑制剂配方
US20180042895A1 (en)	2015-02-26	2018-02-15	Novartis Ag	Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
ES2940306T3 (es)	2015-07-03	2023-05-05	Astellas Pharma Inc	Composición farmacéutica estable para administración oral
US11434200B2 (en)	2017-03-09	2022-09-06	Novartis Ag	Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
US11629124B2 (en)	2017-03-09	2023-04-18	Novartis Ag	Solid forms comprising an oxime ether compound, compositions and methods of use thereof
ES3024636T3 (en)	2017-09-27	2025-06-04	Novartis Ag	Parenteral formulation comprising siponimod
CN111107845A (zh)	2017-09-29	2020-05-05	诺华股份有限公司	西尼莫德的给药方案
KR20200062240A (ko)	2017-09-29	2020-06-03	노파르티스 아게	시포니모드의 투여 요법
CN109908095A (zh) *	2019-04-08	2019-06-21	肇庆学院	一种西尼莫德片剂及制备方法
WO2021214717A1 (en)	2020-04-23	2021-10-28	Novartis Ag	Dosing regimen for the use of siponimod for the treatment of acute respiratory distress syndrome
IL315531A (en) *	2022-03-09	2024-11-01	Isp Investments Llc	The composition of an inactive substance for drugs, produced by joint processing of its components
EP4633611A1 (en)	2022-12-12	2025-10-22	Synthon B.V.	Pharmaceutical composition of siponimod

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3872113A (en)	1972-05-30	1975-03-18	Endo Lab	Hydroxy- and acetoxy-phthalaldehydric acid, O-(substituted) oximes
ES2126658T3 (es)	1992-10-21	1999-04-01	Yoshitomi Pharmaceutical	Compuesto de 2-amino-1,3-propanodiol e inmunosupresor.
AU703933B2 (en)	1994-07-12	1999-04-01	Berwind Pharmaceutical Services, Inc.	Moisture barrier film coating composition, method, and coated form
SI0812588T1 (en)	1995-12-28	2005-02-28	Mitsubishi Pharma Corporation	Pharmaceutical external preparations for topical administration comprising 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol for the treatment of diseases induced from immune disorder
MY121470A (en)	1999-05-03	2006-01-28	Ranbaxy Lab Ltd	Stable solid pharmaceutical compositions containing enalapril maleate
EP1315735A4 (en)	2000-08-31	2005-04-06	Merck & Co Inc	Phosphate derivatives as immunoregulatory compounds
TW200305395A (en)	2002-03-15	2003-11-01	Novartis Ag	Organic compounds
DK1505959T3 (da)	2002-05-16	2009-02-23	Novartis Ag	Anvendelse af EDG-receptorbindingsmidler ved cancer
WO2004041230A1 (ja) *	2002-11-07	2004-05-21	Taisho Pharmaceutical Co.,Ltd.	口腔用組成物用基剤及び口腔用組成物
EP2769713A1 (en)	2003-04-08	2014-08-27	Novartis AG	Solid oral composition comprising a S1P receptor agonist and a sugar alcohol
MY150088A (en)	2003-05-19	2013-11-29	Irm Llc	Immunosuppressant compounds and compositions
CA2524027C (en)	2003-05-19	2013-03-19	Irm Llc	Immunosuppressant compounds and compositions
CL2004001120A1 (es)	2003-05-19	2005-04-15	Irm Llc	Compuestos derivados de amina sustituidas con heterociclos, inmunosupresores; composicion farmaceutica; y uso para tratar enfermedades mediadas por interacciones de linfocito, tales como enfermedades autoinmunes, inflamatorias, infecciosas, cancer.
CA2539033C (en)	2003-09-12	2013-03-05	Neuronova Ab	Treatment of disease or injury of the nervous system with fty720
CA2543045C (en)	2003-10-29	2013-12-17	Wyeth	Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
AU2005237254B2 (en)	2004-05-03	2010-02-04	Novartis Ag	Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
US20060002999A1 (en)	2004-06-17	2006-01-05	Forest Laboratories, Inc.	Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
AU2005309378B2 (en)	2004-11-29	2010-02-11	Novartis Ag	Dosage regimen of an S1P receptor agonist
EP1688141A1 (en)	2005-01-31	2006-08-09	elbion AG	The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
GB0504544D0 (en)	2005-03-04	2005-04-13	Novartis Ag	Organic compounds
RU2296999C2 (ru)	2005-03-09	2007-04-10	Алексей Арнольдович Корженевский	Способ выявления критериев для проведения адекватной иммунотерапии гнойно-септических заболеваний
GT200600350A (es)	2005-08-09	2007-03-28		Formulaciones líquidas
KR20080047538A (ko)	2005-09-09	2008-05-29	라보팜 인코포레이트	서방형 약제 조성물
GB0612721D0 (en)	2006-06-27	2006-08-09	Novartis Ag	Organic compounds
WO2008072056A1 (en)	2006-12-14	2008-06-19	Pfizer Limited	Use of mtp inhibitors for the treatment of obesity using low doses and dose-escalation
DE102007019417A1 (de)	2007-04-23	2008-11-13	Grünenthal GmbH	Tapentadol zur Schmerzbehandlung bei Arthrose
WO2008135522A1 (en)	2007-05-04	2008-11-13	Novartis Ag	Use of s1p receptor modulator
WO2009048993A2 (en) *	2007-10-12	2009-04-16	Novartis Ag	Compositions comprising sphingosine 1 phosphate (s1p) receptor modulators
HRP20170246T4 (hr)	2008-03-17	2020-02-07	Actelion Pharmaceuticals Ltd.	Režim doziranja za selektivni agonist s1p1-receptora
BRPI0914139A2 (pt)	2008-06-20	2015-10-20	Novartis Ag	composições pediátricas para o tratamento de esclerose múltipla
SG10201503157PA (en)	2008-07-23	2015-06-29	Novartis Ag	Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation
WO2010020610A1 (en) *	2008-08-18	2010-02-25	Novartis Ag	Compounds for the treatment of peripheral neuropathies
CN102256942B (zh) *	2008-12-18	2013-07-24	诺瓦提斯公司	1-(4-{1-[(e)-4-环己基-3-三氟甲基-苄氧基亚氨基]-乙基}-2-乙基-苄基)-氮杂环丁烷-3-甲酸的多晶型物
US8486930B2 (en)	2008-12-18	2013-07-16	Novartis Ag	Salts
HRP20131106T1 (hr) *	2008-12-18	2013-12-20	Novartis Ag	Hemifumaratna sol od 1-[4-[1-(4-cikloheksil-3-trifluorometil-benziloksiimino)-etil]-2-etil-benzil]-azetidin-3-karboksilne kiseline
WO2010070083A1 (en)	2008-12-19	2010-06-24	Novartis Ag	Mouthpiece for an inhaler
SI4098256T1 (sl)	2008-12-22	2025-06-30	Novartis Ag	Režim odmerjanja za agonist receptorja s1p
PL2379069T3 (pl)	2008-12-22	2015-08-31	Novartis Ag	Schemat dawkowania agonisty receptora S1P
EP3831371A1 (en)	2009-09-29	2021-06-09	Novartis AG	Dosage regimen of an s1p receptor modulator
PT2661261T (pt)	2011-01-07	2019-10-25	Novartis Ag	Formulações imunossupressoras.
WO2012095853A1 (en)	2011-01-10	2012-07-19	Novartis Pharma Ag	Modified release formulations comprising sip receptor modulators
TW201320994A (zh)	2011-10-11	2013-06-01	Novartis Ag	投藥療程
EP4556908A3 (en)	2013-04-04	2025-07-30	Novartis AG	Identifying patient response to s1p receptor modulator administration
CN106163502B (zh)	2014-04-10	2020-12-01	诺华股份有限公司	免疫抑制剂配方

2012
- 2012-01-05 PT PT127002624T patent/PT2661261T/pt unknown
- 2012-01-05 JO JOP/2012/0005A patent/JO3619B1/ar active
- 2012-01-05 HR HRP20191842TT patent/HRP20191842T1/hr unknown
- 2012-01-05 WO PCT/EP2012/050151 patent/WO2012093161A1/en not_active Ceased
- 2012-01-05 PH PH1/2013/501442A patent/PH12013501442B1/en unknown
- 2012-01-05 MX MX2013007909A patent/MX357304B/es active IP Right Grant
- 2012-01-05 DK DK12700262.4T patent/DK2661261T3/da active
- 2012-01-05 CN CN201280004869.2A patent/CN103458877B/zh active Active
- 2012-01-05 CA CA2823616A patent/CA2823616C/en active Active
- 2012-01-05 EP EP19188018.6A patent/EP3590507A1/en active Pending
- 2012-01-05 PE PE2013001522A patent/PE20140216A1/es active IP Right Grant
- 2012-01-05 MX MX2017007300A patent/MX371290B/es unknown
- 2012-01-05 KR KR1020197004860A patent/KR102166885B1/ko not_active Expired - Fee Related
- 2012-01-05 PL PL12700262T patent/PL2661261T3/pl unknown
- 2012-01-05 KR KR1020137020755A patent/KR101951966B1/ko active Active
- 2012-01-05 UA UAA201307576A patent/UA114283C2/uk unknown
- 2012-01-05 MA MA36170A patent/MA34897B1/fr unknown
- 2012-01-05 LT LT12700262T patent/LT2661261T/lt unknown
- 2012-01-05 BR BR112013017302-5A patent/BR112013017302B1/pt active IP Right Grant
- 2012-01-05 SG SG2013047923A patent/SG191286A1/en unknown
- 2012-01-05 ES ES12700262T patent/ES2751920T3/es active Active
- 2012-01-05 JP JP2013547861A patent/JP6111202B2/ja active Active
- 2012-01-05 AU AU2012204835A patent/AU2012204835B2/en active Active
- 2012-01-05 SI SI201231683T patent/SI2661261T1/sl unknown
- 2012-01-05 EA EA201391018A patent/EA026144B9/ru active Protection Beyond IP Right Term
- 2012-01-05 HU HUE12700262A patent/HUE045612T2/hu unknown
- 2012-01-05 EP EP12700262.4A patent/EP2661261B1/en active Active
- 2012-01-06 TW TW101100702A patent/TWI610672B/zh active
- 2012-01-06 MY MYPI2013002251A patent/MY161162A/en unknown
- 2012-01-06 TW TW104142389A patent/TWI583380B/zh active
- 2012-01-06 AR ARP120100047A patent/AR084801A1/es not_active Application Discontinuation
2013
- 2013-06-14 TN TNP2013000257A patent/TN2013000257A1/fr unknown
- 2013-06-14 US US13/917,730 patent/US20130273161A1/en not_active Abandoned
- 2013-06-18 ZA ZA2013/04465A patent/ZA201304465B/en unknown
- 2013-06-20 IL IL227094A patent/IL227094B/en active IP Right Grant
- 2013-07-05 GT GT201300178A patent/GT201300178A/es unknown
- 2013-07-05 CL CL2013001979A patent/CL2013001979A1/es unknown
- 2013-07-16 CO CO13168667A patent/CO6761402A2/es unknown
- 2013-08-07 EC ECSP13012812 patent/ECSP13012812A/es unknown
2017
- 2017-03-13 JP JP2017047220A patent/JP6324569B2/ja active Active
2019
- 2019-10-22 CY CY20191101097T patent/CY1122182T1/el unknown
2020
- 2020-02-28 US US16/804,926 patent/US20200199069A1/en not_active Abandoned
2021
- 2021-04-14 US US17/230,175 patent/US12071402B2/en active Active
2022
- 2022-01-17 AR ARP220100086A patent/AR124662A2/es unknown
2024
- 2024-08-13 US US18/802,089 patent/US20250084034A1/en active Pending

Also Published As

Publication number	Publication date
US20220064110A1 (en)	2022-03-03
EA201391018A1 (ru)	2013-11-29
TWI583380B (zh)	2017-05-21
ES2751920T3 (es)	2020-04-02
KR20140037815A (ko)	2014-03-27
MX371290B (es)	2020-01-24
AR084801A1 (es)	2013-06-26
KR102166885B1 (ko)	2020-10-19
GT201300178A (es)	2014-12-30
LT2661261T (lt)	2019-10-25
CN103458877A (zh)	2013-12-18
DK2661261T3 (da)	2019-10-21
CA2823616A1 (en)	2012-07-12
JP2017141248A (ja)	2017-08-17
ECSP13012812A (es)	2013-09-30
US20200199069A1 (en)	2020-06-25
PE20140216A1 (es)	2014-03-01
CO6761402A2 (es)	2013-09-30
KR20190025727A (ko)	2019-03-11
US12071402B2 (en)	2024-08-27
CA2823616C (en)	2019-01-29
US20130273161A1 (en)	2013-10-17
MY161162A (en)	2017-04-14
JP2014501770A (ja)	2014-01-23
EA026144B1 (ru)	2017-03-31
PH12013501442B1 (en)	2018-04-20
US20250084034A1 (en)	2025-03-13
EP3590507A1 (en)	2020-01-08
AR124662A2 (es)	2023-04-19
TW201249438A (en)	2012-12-16
PT2661261T (pt)	2019-10-25
CN103458877B (zh)	2016-06-08
BR112013017302B1 (pt)	2021-12-07
AU2012204835B2 (en)	2015-07-09
AU2012204835A1 (en)	2013-08-01
MA34897B1 (fr)	2014-02-01
CL2013001979A1 (es)	2013-11-22
TWI610672B (zh)	2018-01-11
UA114283C2 (uk)	2017-05-25
NZ612420A (en)	2015-05-29
JP6111202B2 (ja)	2017-04-05
ZA201304465B (en)	2014-02-26
HUE045612T2 (hu)	2020-01-28
TW201609092A (zh)	2016-03-16
KR101951966B1 (ko)	2019-02-25
PH12013501442A1 (en)	2013-09-09
MX2013007909A (es)	2013-08-29
JO3619B1 (ar)	2020-08-27
SG191286A1 (en)	2013-07-31
BR112013017302A2 (pt)	2016-10-25
CY1122182T1 (el)	2020-11-25
MX357304B (es)	2018-07-04
WO2012093161A1 (en)	2012-07-12
EA026144B9 (ru)	2021-10-26
IL227094B (en)	2019-03-31
TN2013000257A1 (en)	2014-11-10
EP2661261A1 (en)	2013-11-13
HRP20191842T1 (hr)	2019-12-27
EP2661261B1 (en)	2019-07-31
SI2661261T1 (sl)	2019-11-29
JP6324569B2 (ja)	2018-05-16

Publication	Publication Date	Title
IL227094B (en)	2019-03-31	Immunosuppressive preparations
EP2701734A4 (en)	2016-11-23	LIPOSOMAL FORMULATIONS
GB201111438D0 (en)	2011-08-17	Formulation
ZA201309221B (en)	2014-08-27	Formulation
IL232305B (en)	2019-06-30	Pharmacy preparations
ZA201306016B (en)	2014-04-30	Bendamustine formulations
IL229700B (en)	2018-04-30	Dronvir formulations
GB201114725D0 (en)	2011-10-12	Ophthalmic formulations
EP2765992A4 (en)	2015-04-08	FOAM FORMULATIONS
ZA201402456B (en)	2015-03-25	Formulation
GB201110278D0 (en)	2011-08-03	Formulations
EP2782585A4 (en)	2015-08-05	ANTIVIRAL PREPARATIONS
GB201106958D0 (en)	2011-06-08	Formulation
GB201105360D0 (en)	2011-05-11	Formulations
GB201111578D0 (en)	2011-08-24	Pharmeutical formulations
GB201111013D0 (en)	2011-08-10	Formulations
GB201107627D0 (en)	2011-06-22	Formulations
GB201107626D0 (en)	2011-06-22	Formulations
GB201105410D0 (en)	2011-05-11	Formulations
GB201104049D0 (en)	2011-04-20	Formulations
GB201104048D0 (en)	2011-04-20	Formulations
GB201102795D0 (en)	2011-03-30	Formulations
GB201104284D0 (en)	2011-04-27	Formulation
GB201103767D0 (en)	2011-04-20	Cosmetic formulations
GB201103769D0 (en)	2011-04-20	Cosmetic formulations